These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 33256760)

  • 1. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
    Ikeda K; Chiba H; Nishikiori H; Azuma A; Kondoh Y; Ogura T; Taguchi Y; Ebina M; Sakaguchi H; Miyazawa S; Suga M; Sugiyama Y; Nukiwa T; Kudoh S; Takahashi H;
    Respir Res; 2020 Nov; 21(1):316. PubMed ID: 33256760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.
    Taniguchi H; Kondoh Y; Ebina M; Azuma A; Ogura T; Taguchi Y; Suga M; Takahashi H; Nakata K; Sato A; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Res; 2011 Jul; 12(1):93. PubMed ID: 21756364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
    Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.
    Azuma A; Taguchi Y; Ogura T; Ebina M; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sato A; Kudoh S; Nukiwa T;
    Respir Res; 2011 Oct; 12(1):143. PubMed ID: 22035508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
    Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
    King TE; Bradford WZ; Castro-Bernardini S; Fagan EA; Glaspole I; Glassberg MK; Gorina E; Hopkins PM; Kardatzke D; Lancaster L; Lederer DJ; Nathan SD; Pereira CA; Sahn SA; Sussman R; Swigris JJ; Noble PW;
    N Engl J Med; 2014 May; 370(22):2083-92. PubMed ID: 24836312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia.
    Yamakawa H; Hagiwara E; Ikeda S; Iwasawa T; Otoshi R; Tabata E; Okuda R; Sekine A; Baba T; Iso S; Okudela K; Takemura T; Ogura T
    Respir Investig; 2019 Sep; 57(5):422-429. PubMed ID: 31003951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
    Neighbors M; Cabanski CR; Ramalingam TR; Sheng XR; Tew GW; Gu C; Jia G; Peng K; Ray JM; Ley B; Wolters PJ; Collard HR; Arron JR
    Lancet Respir Med; 2018 Aug; 6(8):615-626. PubMed ID: 30072107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
    Costabel U; Albera C; Bradford WZ; Hormel P; King TE; Noble PW; Sahn SA; Valeyre D; du Bois RM
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):198-205. PubMed ID: 25363219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
    Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
    Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
    Xue M; Guo Z; Cai C; Sun B; Wang H
    Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
    Doubková M; Karpíšek M; Mazoch J; Skřičková J; Doubek M
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Oct; 33(3):224-234. PubMed ID: 27758987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review.
    Zang C; Zheng Y; Wang Y; Li L
    Eur J Med Res; 2021 Oct; 26(1):129. PubMed ID: 34717762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
    Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.